YOKOGAWA-ELECTRIC
16.9.2020 09:02:17 CEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) today revealed the results of a global end-user survey on the outlook for industrial autonomy*, which shows that 64% of respondents from companies in process industries are anticipating fully autonomous operations by 2030. The survey provides an in-depth view of future trends in automation and autonomy, business priorities, and technologies being deployed in key process industries including oil and gas, pharmaceuticals, chemicals, petrochemicals, and power generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005058/en/
Key Insights
Companies are moving to fully autonomous operations by 2030, and will invest in technologies that aid decision-making
Sixty-four percent of respondents stated that they expect to reach autonomous operations in their primary operations by 2030. Eighty-nine percent said their companies currently have plans to increase the level of autonomy in their operations. Regarding their current status, 64% said that they are conducting or are piloting semi-autonomous or autonomous operations, while 67% expect significant automation of most decision-making processes in plant operations by 2023.
Cyber security (51%), cloud, analytics, and big data (47%), and artificial intelligence (42%) are three key areas in which companies are planning significant investment over the next three years. These will enable organizations to make better decisions across a greater span of control.
COVID-19 has put the brakes on economic growth in 2020 but will be a catalyst for the medium- to long-term growth of industrial autonomy.
COVID-19 has arguably presented a great impetus for industrial autonomy moving forward. A higher priority is now being placed on the ability to continue running operations without workers needing to be present. A majority of respondents are expecting to increase their investment in autonomous operations as a direct result of COVID-19.
Respondents were also asked to rank the top four applications in which they were directing investment as a result of the COVID-19 pandemic. Unsurprisingly, remote operations and remote servicing came out as two of the key applications for which priorities have increased, with a respective 36% and 30% of participants selecting them. The ability to conduct work without the need for workers to be present in a hazardous environment provides significant safety and cost benefits.
The survey also uncovered significant differences across industries in post-COVID-19 investment priorities. For example, compared with other industries, conventional power generation and chemical/petrochemical participants placed a greater focus on investments in worker safety.
Regional trends
The survey revealed regional differences in investment in new technologies and the push to industrial autonomy. Relative to other regions, Asia-Pacific is the most engaged in the shift to industrial autonomy. The survey found that the proportion of companies in Asia-Pacific that are prioritizing investment in autonomous systems for operations is 18% to 27% higher than other regions. This is a key statistic and shows that funding is being directed into autonomous operations in the region. Seventy-one percent of respondents in Asia-Pacific felt that they would attain fully autonomous operations in ten years' time, compared with just 58% in North America and 56% in Western Europe.
“From this research study, we have confirmed our perception that the shift from industrial automation to industrial autonomy, which we call IA2IA, is going to gain momentum over the next decade. As COVID-19 will accelerate this trend, and companies' interest in introducing related technologies continues to be strong, Yokogawa can support customers in strengthening their competitiveness step by step based upon our roadmap to autonomous operations,” said Tsuyoshi Abe, senior vice president and head of the Marketing Headquarters at Yokogawa.
Yokogawa believes the digital transformation of companies’ manufacturing and production operations will lead towards autonomous operations; the results of the survey demonstrate that companies are prioritizing and investing in the technologies of tomorrow in order to make this a reality.
The survey highlight report can be downloaded from the following website.
https://www.yokogawa.com/special/ia2ia/outlook/
* The “Global End-user Survey on the Outlook for Industrial Autonomy” was conducted on behalf of Yokogawa by research company Omdia among 504 decision-makers in process industry companies between June and July 2020.
About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 114 companies spanning 62 countries, generating US$3.7 billion in sales in FY2019. For more information, please visit www.yokogawa.com .
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005058/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
